46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the AXPAXLI arm, compared to 0% in the control arm No patients in the AXPAXLI group experienced worsening in DRSS compared to 12.5% in the control arm at 40 weeks AXPAXLI was generally well tolerated with no inflammation observed Ocular intends to present the Phase 1 HELIOS study at an upcoming meeting... Read More

Nadia K. Waheed, MD, MPH, Appointed Chief Medical Officer; Peter K. Kaiser, MD, to Become Chief Development Officer; Andrea Gibson, PhD, Named Vice President, Medical Collaborations; and Namrata Saroj, OD, to Become Development Strategy Consultant Dr. Waheed’s strong industry track record as a CMO and broad expertise in wet AMD and diabetic retinopathy support advancing the Phase 3 AXPAXLI™ program Dr. Kaiser’s vast... Read More

BEDFORD, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that Executive Chairman, Pravin... Read More

BEDFORD, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that it has granted inducement... Read More

Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure (IOP), statistically significant (p<0.0001) through six months, with clinically meaningful reductions of 24-30% achieved with a single PAXTRAVA implant Generally well tolerated with no impact on corneal health observed Consistent durability of IOP reduction and implant bioresorption shows potential for repeat dosing without stacking of... Read More

BEDFORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, announced multiple scientific... Read More

Leadership Appointments Move Ocular Towards Being a Leader in Retinal Care Screening Underway in AXPAXLI™ Phase 3 SOL-1 Trial for Wet AMD Topline Clinical Data for AXPAXLI in Diabetic Retinopathy and PAXTRAVA™ in Glaucoma Expected in Q2 2024 Cash Expected to Support Operations Into At Least 2028 Based on $196M YE 2023 Cash Balance Plus $325M Gross Proceeds from February 2024 PIPE Planning to Host an Investor Day in Q2 2024... Read More

BEDFORD, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for retinal disease and other diseases and conditions of the eye, today announced plans to report the Company’s fourth quarter and full year 2023 financial results... Read More

BEDFORD, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has granted inducement equity awards to its newly appointed Executive Chairman, Pravin U. Dugel, MD and to... Read More

BEDFORD, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq:OCUL) (the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited... Read More

Industry Leader and Retina Expert, Pravin U. Dugel, MD, Becomes Executive Chair Jeffrey S. Heier, MD to become Chief Scientific Officer, Peter K. Kaiser, MD to be Medical Director, and Sanjay Nayak, MBBS, PhD to become Chief Strategy Officer Addition of Strategic and Clinical Experts Puts Ocular on Track to be a Leader in Retina Care Expanded Team Anticipated to Accelerate Momentum in AXPAXLI™ Phase 3 Wet AMD Programs... Read More

SHANGHAI , Feb. 19, 2024 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a biotechnology company dedicated to developing and commercializing transformative pharmaceutical, and surgical products that address critical unmet medical needs in ophthalmology, today announced that the Singapore Health Sciences Authority (HSA) has accepted its New Drug Application (NDA) for DEXTENZA® (0.4 mg dexamethasone ophthalmic insert) for... Read More

BEDFORD, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Steve Meyers as Chief Commercial Officer. “As we continue our commitment to advancing our drug portfolio in order to enhance the quality of life for... Read More

BEDFORD, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the first three subjects have been screened and received their first aflibercept injection in the Phase 3 SOL-1 clinical trial of AXPAXLI™ (axitinib intravitreal... Read More

SPA amendment expands eligibility criteria for SOL clinical trial Broadening of eligibility criteria anticipated to accelerate overall trial enrollment BEDFORD, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the U.S.... Read More

BEDFORD, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the closing of its previously announced underwritten public offering of 35,420,000 shares of its common stock at a public offering price of $3.25 per... Read More

BEDFORD, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the pricing of an underwritten public offering of 30,800,000 shares of its common stock at a public offering price of $3.25 per share for gross... Read More

BEDFORD, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has commenced an underwritten public offering of its common stock. In addition, the Company is expected to grant the underwriters of the... Read More

BEDFORD, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will participate at the following conferences: Jefferies London Healthcare Conference Fireside Chat Date: Wednesday, November 15, 2023 Fireside Chat Time: 3:00... Read More

FDA Agrees to Overall Design of the First Pivotal Trial for AXPAXLI in Wet AMD under a Special Protocol Assessment; Expect First Subject Dosed by Year-End Top-line Data from U.S.-based HELIOS Trial Evaluating AXPAXLI for Treatment of Non-Proliferative Diabetic Retinopathy Anticipated to be Presented in in Q2 2024 Top-line Data from U.S.-based Phase 2 Clinical Trial of OTX-TIC for Treatment of Primary Open-Angle Glaucoma or... Read More

The first subject expected to be dosed by year-end Company announces OTX-TKI trade name AXPAXLI BEDFORD, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced it had received written agreement regarding the overall design from the... Read More

SHANGHAI , Oct. 31, 2023 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmological, neurological and psychiatric disorders, announced positive top-line results from the Real-World Study conducted in the Boao Lecheng Pilot Zone in Hainan,... Read More

BEDFORD, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report third quarter ended September 30, 2023 financial results after the close on Tuesday, November 7, 2023. Following distribution of the earnings... Read More

BEDFORD, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development and commercialization of innovative therapies for diseases and conditions of the eye, today announced the initiation of its first pivotal clinical trial to evaluate OTX-TKI, the Company’s axitinib intravitreal implant, for the treatment of wet age-related macular... Read More

BEDFORD, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will participate at the following conferences: H.C. Wainwright 25th Annual Global Investment Conference Date: Tuesday, September 12, 2023 Ocular Therapeutix™... Read More

BEDFORD, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc . (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will participate in a panel at the H.C. Wainwright 3rd Annual Ophthalmology... Read More

DEXTENZA® Net Product Revenue in Q2 2023 was $15.0 million, Representing Growth of Approximately 24% Over Q2 2022 Closed on a New $82.5 million Credit Facility; Cash Runway Now Forecasted into 2025 First of Two Planned Pivotal Clinical Trials for OTX-TKI in Wet AMD Expected to Initiate in Q3 2023 Completed Enrollment of HELIOS U.S.-based OTX-TKI Phase 1 Clinical Trial for Treatment of Non-Proliferative Diabetic Retinopathy;... Read More

BEDFORD, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report second quarter ended June 30, 2023 financial results after the close on Monday, August 7, 2023. Following distribution of the earnings release via... Read More

BEDFORD, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Adrienne L. Graves, Ph.D., to its Board of Directors. A visual scientist by training and a global industry leader in ophthalmology, Dr. Graves... Read More

OTX-TKI maintained vision and CSFT comparable to aflibercept every eight weeks, with 89% reduction in treatment burden over a 12-month period OTX-TKI demonstrated no drug-related ocular or systemic serious adverse events in the trial through Month 12 Implant observed to bioresorb consistently at about eight to nine months in trial, informing potential redosing timeline Investor/analyst conference call to discuss results to... Read More

BEDFORD, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced completion of enrollment in the HELIOS clinical trial of OTX-TKI. Using Elutyx™ technology, OTX-TKI is the Company’s axitinib intravitreal implant that is being... Read More

BEDFORD, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that 12-month data from the U.S.-based Phase 1 trial evaluating OTX-TKI for the treatment of wet AMD will be presented at the 2023 Clinical Trials at the Summit Annual... Read More

BEDFORD, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will participate in a fireside chat at the Jefferies Global Healthcare Conference... Read More

12-month Top-Line Data from the U.S.-based Phase 1 Clinical Trial of OTX-TKI (axitinib intravitreal implant) for the Treatment of Wet AMD to be Presented in June at the Clinical Trials at the Summit 2023 Meeting Presented Pre-Clinical and Clinical Data on Three Pipeline Programs at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting held April 23rd to 27th DEXTENZA ® Net Product Revenue in the... Read More

BEDFORD, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will participate in a fireside chat at the JMP Securities Life Sciences Conference... Read More

BEDFORD, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple scientific presentations at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting being held May 5-8 in San Diego, California. “We are... Read More

BEDFORD, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report first quarter ended March 31, 2023 financial results after the close on Monday, May 8, 2023. Following distribution of the earnings release via... Read More

BEDFORD, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple scientific presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held April 23 - 27 in New Orleans, Louisiana. “At... Read More

Presented Positive 10-month Interim Data from the U.S.-based Phase 1 Clinical Trial of OTX-TKI (axitinib intravitreal implant) for the Treatment of Wet AMD at the Angiogenesis, Exudation, and Degeneration Annual 2023 Meeting Initiated Phase 1 Clinical Trial of OTX-TKI (axitinib intravitreal implant) for the Treatment of Diabetic Retinopathy in December 2022 Top-Line Data from Phase 2 Clinical Trial of OTX-TIC (travoprost... Read More

BEDFORD, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will participate in a fireside chat at Cowen’s 43rd Annual Healthcare Conference... Read More

BEDFORD, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report fourth quarter and year-end financial results after the close on Monday, March 6, 2023. Following distribution of the earnings release via wire... Read More

All OTX-TKI treated subjects who were rescue-free at the Month 7 interim analysis remained rescue-free, extending the 73% rescue-free rate up to Month 10 CSFT and BCVA measurements at 10 months were comparable between OTX-TKI treated subjects and aflibercept treated subjects OTX-TKI continued to be generally well tolerated with no drug-related serious adverse events through Month 10 Conference call to discuss results to be... Read More

Dextenza ® Net Product Revenue in the Fourth Quarter of 2022 is Estimated to be $13.6 million, Growing Approximately 14% Over Previous Quarter and Approximately 11% Over Same Quarter of Prior Year Dextenza Net Product Revenue for the Year Ending 2022 is Estimated to be $50.2 million, Representing Growth of Approximately 20% Over Prior Year 10-month Interim Data from the U.S.-based Phase 1 Clinical Trial of OTX-TKI (axitinib... Read More